Opioid Use Disorder Clinical Trials

135 studies are recruiting for opioid use disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Using Facebook to Support Opioid Recovery Among American Indian Women

   The purpose of this study is to find out whether a Facebook group will help Native women in recovery from opioid use.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT05995886 on ClinicalTrials.gov

2. A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

   This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   001127, North Canton, Ohio

   Locations

   2 in total

   Run by

   Adneuris Therapeutics, Inc.

   See if you can join NCT07874620 on ClinicalTrials.gov

3. Cannabidiol in Opioid Use Disorder and Chronic Pain With Buprenorphine

   This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with buprenorphine. …

   Stage

   EARLY_Phase 1

   Ages

   18 to 70

   Site

   Department of Veterans Affairs Hospital, West Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07886606 on ClinicalTrials.gov

4. Ketamine for Opioid Use Disorder

   The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder. The main questions it aims to answer are: * Does ketamine reduce craving for opioids in patients with opioid use disorder? * Does ketamine r…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   University of Maryland Addiction Programs and Affiliated Clinics, Baltimore, Maryland

   Run by

   University of Maryland, Baltimore

   See if you can join NCT06943859 on ClinicalTrials.gov

5. Expanding Medication-Assisted Therapies in Central Asia

   Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more eff…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Columbia University Global Health Research Center of Central Asia, Almaty,

   Locations

   4 in total

   Run by

   Yale University

   See if you can join NCT05579470 on ClinicalTrials.gov

6. Supporting Treatment Access and Recovery in COD

   This 4-year study will randomize 1,000 people with co-occurring opioid use and mental health disorders (COD) at medication for opioid use disorder (MOUD) clinics to evaluate the effectiveness of MISSION, a multi-component team approach, or its components with MOUD versus MOUD alone, as well as the …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Behavioral Health Network, Holyoke, Massachusetts

   Locations

   5 in total

   Run by

   University of Massachusetts, Worcester

   See if you can join NCT05138614 on ClinicalTrials.gov

7. Cortical rTMS as a Treatment for Depression

   Depression is a leading cause of disability worldwide with a 19% lifetime prevalence in the United States. Dysfunctional reward processing is one of the core features of depression. Common treatments of depression include psychological therapies (e.g., cognitive behavioral therapy), medication (e.g…

   Stage

   Not phased

   Ages

   18 to 64

   Site

   The Menninger Clinic, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT05487911 on ClinicalTrials.gov

8. Integrating MOUD in Nonmedical Community Settings (Better Together)

   A multisite effectiveness-implementation study will be conducted in four sites to evaluate interventions to improve engagement and retention in MOUD with buprenorphine treatment persons with Opioid Use Disorder (OUD) in urban neighborhoods with high overdose rates. The investigators hypothesize tha…

   Stage

   Not phased

   Ages

   16 and older

   Site

   Howard University, Washington D.C., District of Columbia

   Locations

   4 in total

   Run by

   Howard University

   See if you can join NCT06416020 on ClinicalTrials.gov

9. Semaglutide for Helping Opioid Recovery

   The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06639464 on ClinicalTrials.gov

10. Transcranial Direct Current Stimulation (tDCS) for Treatment of Substance Use Disorder

    The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder or opioid use disorder. Neuroimaging before and after stimulation will establish the neural correlat…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07318480 on ClinicalTrials.gov

11. The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

    Opioid use disorder (OUD) is a chronic relapsing disorder and is well-known for its high-risk rate of overdoses and death. In OUD, sleep and circadian disruptions are highly prevalent, interfere with opioid maintenance treatment outcomes and increase the risk of relapse. So far, commonly used pharm…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06832007 on ClinicalTrials.gov

12. Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

    This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC). Participants who are interested in initia…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Yale School of Medicine, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07176351 on ClinicalTrials.gov

13. Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 Phase

    We are studying whether training an identified support person and providing patient navigation (i.e. a peer recovery specialist assisting you with finding the right support) after delivery can increase "recovery capital"-the resources that help people with opioid use disorder (OUD) stay in treatmen…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Friends Research Institute, Inc.

    See if you can join NCT07787039 on ClinicalTrials.gov

14. A Study of Brenipatide in Participants With Opioid Use Disorder

    The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 14…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    NoesisPharma - Phoenix - East Shea Boulevard, Phoenix, Arizona

    Locations

    61 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07420283 on ClinicalTrials.gov

15. A Bundled Intervention to End Opioid Overdoses

    Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bu…

    Stage

    Phase 4

    Ages

    19 and older

    Site

    UAB, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT07485335 on ClinicalTrials.gov

16. Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

    The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.

    Stage

    Phase 1

    Ages

    25 to 65

    Site

    Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07800520 on ClinicalTrials.gov

17. Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

    This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Community Health Project Los Angeles (CHPLA), Los Angeles, California

    Locations

    8 in total

    Run by

    Montefiore Medical Center

    See if you can join NCT07631598 on ClinicalTrials.gov

18. Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents

    This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention. The intervention involves an Embodied Conversational Agent (ECA), a virtual, animated computer agent designed to simul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Office-Based Addiction Treatment (OBAT) Clinic, BMC, Boston, Massachusetts

    Run by

    Boston Medical Center

    See if you can join NCT06732596 on ClinicalTrials.gov

19. Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD

    This study is to develop and test a medical health application based on cognitive behavioral therapy for insomnia and augmented with other evidence-based sleep interventions that address common sleep-related problems in opioid use disorder. An initial program will be built utilizing input from pers…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06157840 on ClinicalTrials.gov

20. Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder

    The primary objective of this trial is to measure changes in physiologic signals to quantify the status of the autonomic nervous system during opioid withdrawal and cravings.

    Stage

    Not phased

    Ages

    18 to 50

    Site

    Hazelden Betty Ford Foundation, Center City, Minnesota

    Locations

    2 in total

    Run by

    Spark Biomedical, Inc.

    See if you can join NCT06487533 on ClinicalTrials.gov

21. Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder

    The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health…

    Stage

    Not phased

    Ages

    12 to 89

    Site

    UCHealth, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT06526286 on ClinicalTrials.gov

22. Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention

    The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of health resilience and promotion services to be delivered in the hospital setting, called the THRIVE intervention. The main question it aims to answer is: Will participants receiving the THRIVE intervent…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UPMC Presbyterian-Montefiore Hospital, Pittsburgh, Pennsylvania

    Locations

    3 in total

    Run by

    University of Pennsylvania

    See if you can join NCT06843213 on ClinicalTrials.gov

23. A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

    This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07362082 on ClinicalTrials.gov

24. Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

    This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD). Participants will receive TZP or placebo (PBO) daily on Days 2 - 7 during a 7-day inpatient stay at the research center to determine safety, pharmaco…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Indiana University School of Medicine, Indianapolis, Indiana

    Run by

    Proniras Corporation

    See if you can join NCT06538558 on ClinicalTrials.gov

25. Kentucky Women's Justice Community Overdose Innovation Network - Phase II

    This project continues our work with women in the Kentucky Women's Justice Community Overdose Innovation Network Phase II (WJCOIN-II) with the overall aim of reducing overdose risk during the transition from jail to rural communities. WJCOIN-II has potential for significant impact regarding the eff…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Knox County Detention Center, Barbourville, Kentucky

    Locations

    3 in total

    Run by

    Michele Staton

    See if you can join NCT07179614 on ClinicalTrials.gov